CLEC9A and neoplasm: Gene expression analyses have revealed significant heterogeneity among different DC subgroups, particularly a group of type I conventional DCs (CD40, BATF3, CLEC9A, IRF8, and AREG) had a high expression of MHC-II molecules and tumor suppressors, indicating that these cells may be involved in activating adaptive immune response and inhibiting neoplasm.